Adipocytokine signaling pathway
|
T2D
|
3.91E-09
|
18
|
4
|
12
|
2
|
Neuroactive ligand-receptor interaction
|
SCZ
|
4.01E-09
|
35
|
26
|
9
|
0
|
Maturity onset diabetes of the young
|
T2D
|
1.94E-08
|
11
|
0
|
11
|
0
|
Type II diabetes mellitus
|
T2D
|
1.98E-08
|
14
|
1
|
12
|
1
|
PPAR signaling pathway
|
T2D
|
9.33E-07
|
15
|
2
|
13
|
0
|
Calcium signaling pathway
|
SCZ
|
5.03E-06
|
23
|
18
|
5
|
0
|
Visceral Fat Deposits and the Metabolic Syndrome
|
T2D
|
6.57E-05
|
5
|
0
|
4
|
1
|
Type I diabetes mellitus
|
SCZ
|
7.12E-05
|
10
|
8
|
1
|
1
|
Corticosteroids and cardioprotection
|
BOTH
|
8.96E-05
|
6
|
3
|
2
|
1
|
Low-density lipoprotein (LDL) pathway during atherogenesis
|
T2D
|
3.28E-04
|
4
|
0
|
4
|
0
|
Insulin signaling pathway
|
T2D
|
9.20E-04
|
16
|
1
|
15
|
0
|
Graft-versus-host disease
|
SCZ
|
0.001587097
|
8
|
6
|
1
|
1
|
IL-10 Anti-inflammatory Signaling Pathway
|
BOTH
|
0.001671861
|
4
|
1
|
1
|
2
|
Basic mechanism of action of PPARa, PPARb(d) and PPARg and effects on gene expression
|
T2D
|
0.001780493
|
3
|
0
|
3
|
0
|
Actions of Nitric Oxide in the Heart
|
BOTH
|
0.002369651
|
5
|
2
|
3
|
0
|
Erythropoietin mediated neuroprotection through NF-kB
|
BOTH
|
0.003426765
|
4
|
2
|
1
|
1
|
Allograft rejection
|
SCZ
|
0.003509
|
7
|
5
|
0
|
2
|
g-Secretase mediated ErbB4 Signaling Pathway
|
SCZ
|
0.005740212
|
3
|
3
|
0
|
0
|
Msp/Ron Receptor Signaling Pathway
|
BOTH
|
0.005740212
|
3
|
1
|
1
|
1
|
Autoimmune thyroid disease
|
SCZ
|
0.020029548
|
7
|
6
|
0
|
1
|
Alzheimer's disease
|
BOTH
|
0.020096651
|
5
|
1
|
2
|
2
|
Free Radical Induced Apoptosis
|
SCZ
|
0.020961818
|
3
|
2
|
0
|
1
|
Role of PPAR-gamma Coactivators in Obesity and Thermogenesis
|
T2D
|
0.020961818
|
3
|
0
|
3
|
0
|
Asthma
|
SCZ
|
0.023911463
|
5
|
3
|
0
|
2
|
AKT Signaling Pathway
|
SCZ
|
0.024540904
|
4
|
3
|
1
|
0
|
Hematopoietic cell lineage
|
BOTH
|
0.027660527
|
9
|
4
|
4
|
1
|
Regulation of PGC-1a
|
T2D
|
0.029865431
|
3
|
1
|
2
|
0
|
Role of ERBB2 in Signal Transduction and Oncology
|
T2D
|
0.030339933
|
4
|
1
|
3
|
0
|